Literature DB >> 1607079

Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus.

M J Rowley1, I R Mackay, Q Y Chen, W J Knowles, P Z Zimmet.   

Abstract

Insulin-dependent diabetes mellitus (IDDM) is marked by circulating antibodies to a 64,000-M(r) islet cell antigen identified as glutamic acid decarboxylase (GAD). We describe a radioimmunoprecipitation assay with GAD isolated from pig brain. The sera tested were from 80 patients with IDDM including 26 with disease of recent onset and 54 with disease of longer duration (3-42 yr), 20 with non-insulin-dependent diabetes mellitus (NIDDM), and 55 nondiabetic subjects. Conventional assays for islet cell cytoplasmic antibodies were performed concurrently. The level of antibody in serum was expressed in units based on percentage reactivity of a standard reference serum. The frequency of antibody to GAD in IDDM was 69% in short-duration cases and 59% in long-duration cases. The latter was substantially higher than the frequency of islet cell cytoplasmic antibody. Antibodies to GAD were elevated (means +/- 3 SD) in 5% NIDDM cases and in none of the nondiabetic subjects. A simple laboratory test with a defined autoantigen has substantial implications for population screening and early diagnosis of IDDM and for better understanding of its pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607079     DOI: 10.2337/diab.41.4.548

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  22 in total

1.  Autoantibodies in recent onset type-1 diabetic patients to a Mr 60K microsomal hepatic protein: new evidence for autoantibodies to the type-2 glucose transporter.

Authors:  M Pehuet-Figoni; F Alvarez; J F Bach; L Chatenoud
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 2.  Latent autoimmune diabetes in adults (LADA).

Authors:  Ramachandra G Naik; Jerry P Palmer
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

3.  Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders.

Authors:  A C Powers; K Bavik; J Tremble; K Daw; W A Scherbaum; J P Banga
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 4.  Prediction and prevention of type I diabetes.

Authors:  R Gianani; G S Eisenbarth
Journal:  J Endocrinol Invest       Date:  1994 Jul-Aug       Impact factor: 4.256

5.  GAD 65 antibody but not ICA positivity in adult-onset diabetic patients is associated with early progression to clinical insulin dependency.

Authors:  E Hatziagelaki; C Jaeger; E Maeser; R G Bretzel; K Federlin
Journal:  Acta Diabetol       Date:  1996-12       Impact factor: 4.280

6.  Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets.

Authors:  Kathrin Maedler; Pavel Sergeev; Frédéric Ris; José Oberholzer; Helen I Joller-Jemelka; Giatgen A Spinas; Nurit Kaiser; Philippe A Halban; Marc Y Donath
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

7.  Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in type 1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression.

Authors:  L A Velloso; O Kämpe; A Hallberg; L Christmanson; C Betsholtz; F A Karlsson
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

Review 8.  Syndromes of ketosis-prone diabetes mellitus.

Authors:  Ashok Balasubramanyam; Ramaswami Nalini; Christiane S Hampe; Mario Maldonado
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

9.  Longitudinal changes in epitope recognition of autoantibodies against glutamate decarboxylase 65 (GAD65Ab) in prediabetic adults developing diabetes.

Authors:  C S Hampe; T R Hall; A Agren; O Rolandsson
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

Review 10.  Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes.

Authors:  Marc Y Donath; Joachim Størling; Kathrin Maedler; Thomas Mandrup-Poulsen
Journal:  J Mol Med (Berl)       Date:  2003-07-18       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.